Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $1.2 million.

  • Lineage Cell Therapeutics' Share-based Compensation fell 984.96% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 304.85%. This contributed to the annual value of $5.1 million for FY2024, which is 941.81% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Share-based Compensation of $1.2 million as of Q3 2025, which was down 984.96% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Share-based Compensation peaked at $1.3 million during Q3 2024, and registered a low of $539000.0 during Q1 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' median Share-based Compensation value was $1.2 million (recorded in 2024), while the average stood at $1.1 million.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Share-based Compensation in the last 5 years was 12834.33% (2021), contrasted with its biggest fall of 1389.78% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Share-based Compensation (Quarter) stood at $918000.0 in 2021, then rose by 4.47% to $959000.0 in 2022, then increased by 10.53% to $1.1 million in 2023, then rose by 24.06% to $1.3 million in 2024, then decreased by 8.82% to $1.2 million in 2025.
  • Its Share-based Compensation was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.2 million in Q1 2025.